Dr. Rubin Goes the Distance for ALS Research

Dr. Adam D. Rubin has seen the destructive effects of ALS, more commonly known as Lou Gehrig’s disease, both personally and professionally. So it makes sense that the 44-year-old laryngologist would blend his love of running with his desire to find a cure for this devastating disease.

That is why Dr. Rubin planned to run his first New York City Marathon on Nov. 4 to raise funds for ALS research.  And while the run was canceled following Hurricane Sandy, Dr. Rubin is continuing to fundraise and will run the Anthem Richmond marathon on Nov. 10 in Virginia.

Donations will go to the Program for Neurology Research & Discovery (PNRD) at the University of Michigan Health System, a laboratory directed by Dr. Eva Feldman with which Dr. Rubin has been affiliated for years.

So far, Dr. Rubin and his teammates (friends who will also be running) have received donations of nearly $9,000. That far surpasses his initial expectations when he started training in August for the grueling 26.2 mile race. Now, the determined doctor has set his eyes on raising $15,000 through CrowdRise, an online fund-raising site.

“It started off as a challenge for me, but I also thought it was a great opportunity to do a fundraiser as well. It’s been a lot of fun,” except for some aching legs and knees, Dr. Rubin said. “When I first started this, I didn’t know what to expect. In a lot of ways, now I’m more passionate about the fundraising than the running.”

This run – along with his work with U-M – are dedicated to his own patients and to the memory of a family friend who recently lost his battle with ALS, Dr. Rubin said.

“We recently lost a wonderful neighbor, Dr. Eric Baron, to the disease process,” Dr. Rubin stated. “He was a brilliant physician, entrepreneur and father. He battled the disease for eight years, making every effort to stay alive as long as possible to watch his infant daughter grow. He remained positive and determined, and truly touched the heart of all the people around him. He remains an inspiration to me and my family.”

Amyotrophic lateral sclerosis, or ALS, is a disease of the nerve cells that control voluntary muscle movement. It causes the death of these motor neurons within the brainstem and spinal cord, Dr. Rubin explained, and is a progressive disease that usually leads to death within five years of diagnosis. As neurons die, patients lose the ability to voluntarily move body parts, and eventually, to breathe. When the brainstem is involved, patients lose the ability to speak and swallow. All the while, patients suffering from this disorder stay completely aware of their bodies deteriorating.

Although there currently is no effective treatment for ALS, Dr. Feldman is leading the first FDA-approved human clinical trial of a stem cell treatment for ALS, which is taking place at Emory University in Atlanta. Contributions to Dr. Rubin’s run will go toward improving the procedure and expanding the clinical trial.

As director of the Lakeshore Professional Voice Center PC in St. Clair Shores, the laryngologist said he sees three to five patients a year who come to him believing they have voice problems only for Dr. Rubin to find they have early indicators of ALS.

A native of Huntington Woods and a graduate of the Harvard Medical School, Dr. Rubin’s own basic science interests include using gene therapy to regenerate nerves of the larynx that have been damaged by injury or disease. He began his collaboration with Dr. Feldman, who is also the director of the A. Alfred Taubman Medical Research Institute at U-M, as a resident, during which time he received the U-M Merle Lawrence Basic Science Research and the John L. Kemink Clinical Research Awards.

Many of Dr. Rubin’s donations have come from colleagues, family and friends whose lives have been touched by ALS in some form. He also has spread the word about his fund-raising efforts through social-media outlets such as Twitter (@VoiceDocintheD) and Facebook.

“You might think of it as a rare disease, but a lot of people have a connection to it,” Dr. Rubin said. “It’s amazing – everyone has been incredibly supportive.”

For more information or to donate to Dr. Rubin’s cause, please go to:  http://www.crowdrise.com/adamnycrun/fundraiser/adamrubin


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift


Follow Us / Friend Us

Discovery-driven research that matters


Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding


The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more

Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  


Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster


video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists